Explore more publications!
Iowa Healthcare Reporter
Got News to Share?

Iowa Healthcare Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Iowa Healthcare Reporter.

February 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28

March 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

Press releases published on April 16, 2026

Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
2 hours ago

Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

Indeterminate GlobeNewswire
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
2 hours ago

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Indeterminate GlobeNewswire
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
3 hours ago

Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026

Indeterminate GlobeNewswire
Alethio Therapeutics Unveils ATX‑011, a Breakthrough, Mutation‑Agnostic Antibody for Treating Essential Thrombocythemia – a c.$2B Market, and Strengthens Leadership to Accelerate Path to IND
4 hours ago

Alethio Therapeutics Unveils ATX‑011, a Breakthrough, Mutation‑Agnostic Antibody for Treating Essential Thrombocythemia – a c.$2B Market, and Strengthens Leadership to Accelerate Path to IND

Indeterminate GlobeNewswire
Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure
5 hours ago

Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure

Indeterminate GlobeNewswire
STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15
5 hours ago

STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15

Indeterminate GlobeNewswire
ATOSS unterstützt Charité bei der Workforce Management-Modernisierung
5 hours ago

ATOSS unterstützt Charité bei der Workforce Management-Modernisierung

Indeterminate GlobeNewswire
CancerVax to Target Colorectal Cancer Following Recent Biodistribution Breakthroughs
5 hours ago

CancerVax to Target Colorectal Cancer Following Recent Biodistribution Breakthroughs

Indeterminate GlobeNewswire
Greywolf Therapeutics appoints Edwin Moses as Chair
6 hours ago

Greywolf Therapeutics appoints Edwin Moses as Chair

Indeterminate GlobeNewswire
ONWARD Medical Successfully Raises over EUR 40 Million in Capital Increase
7 hours ago

ONWARD Medical Successfully Raises over EUR 40 Million in Capital Increase

Indeterminate GlobeNewswire
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
7 hours ago

BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100

Indeterminate GlobeNewswire
UroFlow Claims Evaluated: Reviewing the Official Website Benefits & Ingredients to Support Prostate Health
10 hours ago

UroFlow Claims Evaluated: Reviewing the Official Website Benefits & Ingredients to Support Prostate Health

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions